Qnovia, Inc. Announces First Patient Dosed in U.S. in Phase 1 study for RespiRx™ Nicotine Inhaler as a prescription smoking cessation therapy
- RespiRx™ Nicotine Inhaler is the world's first truly inhalable nicotine replacement therapy -
- RespiRx™ Nicotine Inhaler is the world's first truly inhalable nicotine replacement therapy -
Please help local businesses by taking an online survey to help us navigate through these unprecedented times. None of the responses will be shared or used for any other purpose except to better serve our community. The survey is at: www.pulsepoll.com $1,000 is being awarded. Everyone completing the survey will be able to enter a contest to Win as our way of saying, "Thank You" for your time. Thank You!